Contact
searchSearch
HMP Global

First Report Managed Care

News

News
Medicare Advantage Associated With Reduced Utilization of Discretionary Procedures Across Racial and Ethnic Groups
10/14/2026
Rebecca Amrick
Researchers found that Medicare Advantage beneficiaries had lower utilization of discretionary procedures compared to traditional Medicare, with the greatest difference being observed among White beneficiaries.
Researchers found that Medicare Advantage beneficiaries had lower utilization of discretionary procedures compared to traditional Medicare, with the greatest difference being observed among White beneficiaries.
Researchers found that Medicare...
10/14/2026
First Report Managed Care
News
Semaglutide and Tirzepatide Demonstrate Long-Term Cost-Effectiveness Among Patients With MASH
10/13/2026
Rebecca Amrick
In a cost-effective analysis of pharmacotherapies, semaglutide and tirzepatide demonstrated better cost-effectiveness than standard of care among patients with metabolic dysfunction‐associated steatohepatitis (MASH).
In a cost-effective analysis of pharmacotherapies, semaglutide and tirzepatide demonstrated better cost-effectiveness than standard of care among patients with metabolic dysfunction‐associated steatohepatitis (MASH).
In a cost-effective analysis of...
10/13/2026
First Report Managed Care
News
Axi-Cel and Tisa-Cel Show Comparable Adjusted Efficacy in Relapsed or Refractory Follicular Lymphoma
10/13/2026
Rebecca Amrick
In an analysis of patients with relapsed or refractory follicular lymphoma receiving chimeric antigen receptor (CAR) T-cell therapy, axicabtagene ciloleucel (axi-cel) was associated with improved effectiveness and higher toxicity compared to...
In an analysis of patients with relapsed or refractory follicular lymphoma receiving chimeric antigen receptor (CAR) T-cell therapy, axicabtagene ciloleucel (axi-cel) was associated with improved effectiveness and higher toxicity compared to...
In an analysis of patients with...
10/13/2026
First Report Managed Care
News
Asciminib Associated With Durable Molecular Responses Among Patients With CML-CP
10/09/2026
Rebecca Amrick
Researchers found that asciminib 200 mg twice daily demonstrated significant efficacy and manageable toxicity among patients with T315I-mutated chronic myeloid leukemia in chronic phase (CML-CP).
Researchers found that asciminib 200 mg twice daily demonstrated significant efficacy and manageable toxicity among patients with T315I-mutated chronic myeloid leukemia in chronic phase (CML-CP).
Researchers found that asciminib...
10/09/2026
First Report Managed Care
Behind the Bill
New Federal Rule Strengthens Health Insurer Price Transparency Standards
10/09/2026
Hannah Musick
Federal regulators have finalized new health insurance price transparency requirements aimed at improving pricing disclosures, strengthening consumer access to cost information, and streamlining reporting obligations for health plans and...
Federal regulators have finalized new health insurance price transparency requirements aimed at improving pricing disclosures, strengthening consumer access to cost information, and streamlining reporting obligations for health plans and...
Federal regulators have...
10/09/2026
First Report Managed Care
News
US Study Identifies Survival Trends and Disparities Across Myeloproliferative Neoplasms
10/09/2026
Hannah Musick
A US population-based study of more than 63 000 patients with myeloproliferative neoplasms identified improved survival in primary myelofibrosis alongside persistent differences in incidence and survival across disease subtypes, age groups,...
A US population-based study of more than 63 000 patients with myeloproliferative neoplasms identified improved survival in primary myelofibrosis alongside persistent differences in incidence and survival across disease subtypes, age groups,...
A US population-based study of...
10/09/2026
First Report Managed Care
News
Mosunetuzumab Associated With Improved Survival Among Patients With Relapsed or Refractory FL
10/09/2026
Rebecca Amrick
Researchers found that mosunetuzumab was associated with high response rates and manageable safety among patients with relapsed or refractory follicular lymphoma (FL), even those who do not qualify for clinical trials.
Researchers found that mosunetuzumab was associated with high response rates and manageable safety among patients with relapsed or refractory follicular lymphoma (FL), even those who do not qualify for clinical trials.
Researchers found that...
10/09/2026
First Report Managed Care
News
Ruxolitinib Cream Improves Moderate Atopic Dermatitis After Prior Topical Treatment Failure
10/08/2026
Hannah Musick
In the phase 3 TRuE-AD4 trial, ruxolitinib cream significantly improved disease severity, itch, and quality of life among adults with moderate atopic dermatitis who had not responded adequately to conventional topical therapies, potentially...
In the phase 3 TRuE-AD4 trial, ruxolitinib cream significantly improved disease severity, itch, and quality of life among adults with moderate atopic dermatitis who had not responded adequately to conventional topical therapies, potentially...
In the phase 3 TRuE-AD4 trial,...
10/08/2026
First Report Managed Care
News
Service Utilization in Full-Risk Contracts May Inform Physician Fee Schedule Reform
10/07/2026
Rebecca Amrick
Researchers found that full-risk contracts were associated with variations in service utilization patterns, providing potential benchmarks which could help inform physician fee schedule reforms.
Researchers found that full-risk contracts were associated with variations in service utilization patterns, providing potential benchmarks which could help inform physician fee schedule reforms.
Researchers found that full-risk...
10/07/2026
First Report Managed Care
Behind the Bill
CMS Finalizes GLOBE Model Linking Medicare Part B Drug Rebates to International Prices
10/02/2026
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) has finalized the Global Benchmark for Efficient Drug Pricing (GLOBE) Model, linking certain Medicare Part B drug rebates to international prices in an effort to lower federal spending and...
The Centers for Medicare & Medicaid Services (CMS) has finalized the Global Benchmark for Efficient Drug Pricing (GLOBE) Model, linking certain Medicare Part B drug rebates to international prices in an effort to lower federal spending and...
The Centers for Medicare &...
10/02/2026
First Report Managed Care

KOL Insights

Interview
Improving Care Transitions to Reduce Avoidable Emergency Department Use
09/29/2026
Hamad Husainy, DO, FACEP
Hamad Husainy, DO, FACEP, discusses opportunities to strengthen care transitions, improve data sharing, and reduce avoidable emergency department visits and hospital readmissions.
Hamad Husainy, DO, FACEP, discusses opportunities to strengthen care transitions, improve data sharing, and reduce avoidable emergency department visits and hospital readmissions.
Hamad Husainy, DO, FACEP,...
09/29/2026
First Report Managed Care
MANAGED CARE Q&A
Pharmacist-Led Medication Optimization Shows Growing Cost Savings in Accountable Care Organizations
09/29/2026
Travis Morgan
In this interview, Travis Morgan, CPA, MBA, discusses how a pharmacist-led medication optimization program targeting polypharmacy among Medicare accountable care organization beneficiaries was associated with increasing reductions in total...
In this interview, Travis Morgan, CPA, MBA, discusses how a pharmacist-led medication optimization program targeting polypharmacy among Medicare accountable care organization beneficiaries was associated with increasing reductions in total...
In this interview, Travis...
09/29/2026
First Report Managed Care
MANAGED CARE Q&A
Moving SDOH Programs Beyond Referrals to Measurable Outcomes
09/29/2026
Rakshith Yashvanth
In this interview, Rakshith Yashvanth discusses how health plans can move SDOH programs beyond referrals by strengthening community partnerships, reducing administrative burden, and using linked data to measure service delivery and long-term...
In this interview, Rakshith Yashvanth discusses how health plans can move SDOH programs beyond referrals by strengthening community partnerships, reducing administrative burden, and using linked data to measure service delivery and long-term...
In this interview, Rakshith...
09/29/2026
First Report Managed Care
Regulatory Insights
Health Care Policy Debates to Watch Ahead of the 2026 Midterms
09/29/2026
Adam Colborn, JD
As the 2026 midterm elections approach, Senate Finance Committee proposals, competing 340B reform bills, and bipartisan Medicare legislation offer insight into the health care priorities that could shape the next Congress.
As the 2026 midterm elections approach, Senate Finance Committee proposals, competing 340B reform bills, and bipartisan Medicare legislation offer insight into the health care priorities that could shape the next Congress.
As the 2026 midterm elections...
09/29/2026
First Report Managed Care
Commentary
Hospital Leaders Assess Financial and Operational Effects of the FY 2027 CMS IPPS Final Rule
09/29/2026
Hass Saad, MD; Fawad Butt; Tomas Bednar; Eugene Gonsiorek; David Feldman, MD; Bob Watson; Ronald F. Dixon, MD
Health care leaders discuss how the FY 2027 CMS inpatient payment rule may shape hospital finances, digital infrastructure, care coordination, and readiness for nationwide joint replacement bundles.
Health care leaders discuss how the FY 2027 CMS inpatient payment rule may shape hospital finances, digital infrastructure, care coordination, and readiness for nationwide joint replacement bundles.
Health care leaders discuss how...
09/29/2026
First Report Managed Care
Ben Derman
Interview
Navigating the Next Phase of Multiple Myeloma Treatment: Balancing Innovation, Access, and Evidence
07/23/2026
Ben Derman, MD
In this interview, a guest expert shares insights discussed at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting about the updated ASCO Living Guideline for multiple myeloma, including broader use of quadruplet regimens,...
In this interview, a guest expert shares insights discussed at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting about the updated ASCO Living Guideline for multiple myeloma, including broader use of quadruplet regimens,...
In this interview, a guest...
07/23/2026
First Report Managed Care
PIPELINE PROJECTIONS
The Evolving Alzheimer Disease Treatment Landscape: Anti-Amyloid Therapies and Beyond
07/21/2026
Roy Moore
Roy Moore explores the evolving Alzheimer's disease pipeline, highlighting the promise of anti-amyloid therapies, emerging competitors, and the challenges ahead.
Roy Moore explores the evolving Alzheimer's disease pipeline, highlighting the promise of anti-amyloid therapies, emerging competitors, and the challenges ahead.
Roy Moore explores the evolving...
07/21/2026
First Report Managed Care
LC
Interview
The Next Phase of Value-Based Care: From Evidence to Implementation
07/20/2026
Lynn Carroll
In this interview, a guest expert discusses how health plans are evaluating innovative therapies through the lens of value-based care and explains why real-world evidence, interoperable data, and scalable contract infrastructure are essential...
In this interview, a guest expert discusses how health plans are evaluating innovative therapies through the lens of value-based care and explains why real-world evidence, interoperable data, and scalable contract infrastructure are essential...
In this interview, a guest...
07/20/2026
First Report Managed Care
J Collins
Commentary
Time is Therapy: What Managed Care Can Learn from Individuals Navigating Infusion Access
07/14/2026
Jessica Collins, MBA
A patient panel at the 2026 National Infusion Center Association (NICA) Annual Conference underscored how delays driven by prior authorization, benefit design, and administrative barriers can profoundly affect the lives of individuals with...
A patient panel at the 2026 National Infusion Center Association (NICA) Annual Conference underscored how delays driven by prior authorization, benefit design, and administrative barriers can profoundly affect the lives of individuals with...
A patient panel at the 2026...
07/14/2026
First Report Managed Care
BI FRMC KOL video
Videos
Beyond FVC: What FIBRONEER-ILD Means for Outcomes, Patients, and Access in PPF
07/01/2026
Toby Maher, MD, PhD
In this expert commentary, Dr Toby Maher discusses the evolving treatment landscape in progressive pulmonary fibrosis (PPF) and the potential implications of the longer-term FIBRONEER-ILD trial findings. He explores how nerandomilast may...
In this expert commentary, Dr Toby Maher discusses the evolving treatment landscape in progressive pulmonary fibrosis (PPF) and the potential implications of the longer-term FIBRONEER-ILD trial findings. He explores how nerandomilast may...
In this expert commentary, Dr...
07/01/2026
First Report Managed Care

Issue Features

Special Article
FIBRONEER-ILD Extended Follow-Up: What Nerandomilast Means for PPF Care
06/25/2026
This article reviews the extended follow-up findings from the Phase III FIBRONEER-ILD trial and examines the potential implications of nerandomilast for the management of PPF. It highlights the durability of lung function benefits, clinically...
This article reviews the extended follow-up findings from the Phase III FIBRONEER-ILD trial and examines the potential implications of nerandomilast for the management of PPF. It highlights the durability of lung function benefits, clinically...
This article reviews the...
06/25/2026
First Report Managed Care
Infographic
Extended Findings With Nerandomilast in Idiopathic Pulmonary Fibrosis (IPF)
05/21/2026
The infographic summarizes 76-week study data from the phase 3 FIBRONEER-IPF trial to provide additional insights on lung function trends, disease progression, mortality risk, and safety outcomes over time with nerandomilast.
The infographic summarizes 76-week study data from the phase 3 FIBRONEER-IPF trial to provide additional insights on lung function trends, disease progression, mortality risk, and safety outcomes over time with nerandomilast.
The infographic summarizes...
05/21/2026
First Report Managed Care
Sponsored
Explore the Clinical Data for JOURNAVX® (suzetrigine)
10/16/2025
JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain in adults—the first and only oral pain signal inhibitor highly selective for NaV1.81
JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain in adults—the first and only oral pain signal inhibitor highly selective for NaV1.81
JOURNAVX is an oral nonopioid...
10/16/2025
First Report Managed Care
Infographic
Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis
08/06/2025
The infographic summarizes the FIBRONEER-IPF Phase 3 trial results, demonstrating nerandomilast significantly reduced the decline in forced vital capacity (FVC) over 52 weeks compared to placebo. Nerandomilast exhibited a favorable safety...
The infographic summarizes the FIBRONEER-IPF Phase 3 trial results, demonstrating nerandomilast significantly reduced the decline in forced vital capacity (FVC) over 52 weeks compared to placebo. Nerandomilast exhibited a favorable safety...
The infographic summarizes the...
08/06/2025
First Report Managed Care
Feature Story
More Specialists Should Gravitate Toward Episode-Based Care Models
05/12/2025
Lynn Carroll; Rahul Sharma
Health care organizations will be under increasing financial pressure in 2025 and beyond as they struggle to reduce costs while improving care quality—particularly as actions at the federal level threaten to severely disrupt the industry. Not...
Health care organizations will be under increasing financial pressure in 2025 and beyond as they struggle to reduce costs while improving care quality—particularly as actions at the federal level threaten to severely disrupt the industry. Not...
Health care organizations will...
05/12/2025
First Report Managed Care

Interactive Features

Poll
Evaluating Treatment Options for Advanced Squamous Cell Carcinoma of the Anal Canal
06/18/2026
Do you think retifanlimab plus carboplatin/paclitaxel should be adopted as the new frontline standard of care for patients with advanced squamous cell carcinoma of the anal canal?
Do you think retifanlimab plus carboplatin/paclitaxel should be adopted as the new frontline standard of care for patients with advanced squamous cell carcinoma of the anal canal?
Do you think retifanlimab plus...
06/18/2026
First Report Managed Care
Quiz
First-Line Immunotherapy in Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC): Pre-Test
03/31/2026
03/31/2026
First Report Managed Care
PIPELINE PROJECTIONS
Emerging Therapies Reshaping Atopic Dermatitis Care
03/26/2026
Roy Moore
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly...
03/26/2026
First Report Managed Care
Quiz
Monitoring AI Automation
11/25/2025
True or False: The transformation of traditional health care call centers into “smart access hubs” relies entirely on artificial intelligence (AI) to manage all patient interactions and scheduling.
True or False: The transformation of traditional health care call centers into “smart access hubs” relies entirely on artificial intelligence (AI) to manage all patient interactions and scheduling.
True or False: The...
11/25/2025
First Report Managed Care
Quiz
Mobile Health’s Expanding Role in Bridging Care Gaps Across the US
11/11/2025
11/11/2025
First Report Managed Care

Pipeline Projections

PIPELINE PROJECTIONS
The Evolving Alzheimer Disease Treatment Landscape: Anti-Amyloid Therapies and Beyond
07/21/2026
Roy Moore
Roy Moore explores the evolving Alzheimer's disease pipeline, highlighting the promise of anti-amyloid therapies, emerging competitors, and the challenges ahead.
Roy Moore explores the evolving Alzheimer's disease pipeline, highlighting the promise of anti-amyloid therapies, emerging competitors, and the challenges ahead.
Roy Moore explores the evolving...
07/21/2026
First Report Managed Care
PIPELINE PROJECTIONS
Emerging Therapies Reshaping Atopic Dermatitis Care
03/26/2026
Roy Moore
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly...
03/26/2026
First Report Managed Care
Pipe
Pipeline Projections
Emerging Migraine Treatments Challenge a Mature Market
11/20/2025
Roy Moore
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market...
11/20/2025
First Report Managed Care
Pipeline Projections
Pipeline Projections
Redefining Asthma Management With Emerging Anti-Inflammatories
10/01/2025
Roy Moore
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access...
10/01/2025
First Report Managed Care
Pipeline Projections
The Shift in MS Care as Biologics and BTK Inhibitors Advance
07/25/2025
Roy Moore
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline...
07/25/2025
First Report Managed Care

Subscribe to receive the latest updates in managed care!

First Report Managed Care Newsletter

Behind the Bill

Behind the Bill
HHS Hits Reset on 340B Rebate Model After Court Setbacks
02/11/2026
Juliet Gallagher
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and...
02/11/2026
First Report Managed Care
Behind the Bill
Funding Package Extends Medicare Telehealth, Enacts PBM Reforms, and Updates Hospital Oversight
02/05/2026
Juliet Gallagher
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President...
02/05/2026
First Report Managed Care
Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use